Sylentis presented preclinical results of a new topically administered molecule (SYL1801), indicated for the treatment of age-related macular degeneration (AMD), at the ARVO meeting.
Sylentis presented the abstract “Topical administration of siRNA targeting NRARP as a new treatment for choroidal neovascularization” (Posterboard Number: 2634 – A0139), in which SYL1801 is evaluated for its role upon NRARP, a protein that controls the formation of new blood cells in the retina.
“Macular degeneration is the primary cause of loss of vision in people over 50 years of age. The current treatments involve intravitreal infections, so at Sylentis we are trying to develop products that are of a topical use for this illness, therefore, in addition to the treatment, we would also be improving the quality of life of our patients,” Ana Isabel Jiménez, Director of R&D at Sylentis, said in a company news release.
About RNA interference https://www.youtube.com/watch?v=iXvSitR5184